* Boston Scientific outlines strategy for sustained growth at 2017 investor day

* Continues to expect to launch Lotus Edge valve system in Europe and submit U.S. pre-market approval submission in Q4 of 2017

* Company expects to introduce vercise dbs system in U.S. by early 2018, pending regulatory approval

* Goal is to achieve an organic revenue compound annual growth rate for 2018-2020 of six to eight percent

* Goal is to achieve consistent double-digit adjusted EPS growth for 2018-2020

* Five-year growth strategy intended to help reach a 25 percent adjusted operating margin in 2017 and 28 percent in 2020 Source text for Eikon: Further company coverage: